Dyne Therapeutics, Inc.
DYN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $97 | $99 | $106 | $82 |
| G&A Expenses | $17 | $17 | $16 | $15 |
| SG&A Expenses | $17 | $17 | $16 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $114 | $116 | $122 | $97 |
| Operating Income | -$114 | -$116 | -$122 | -$97 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6 | $5 | $7 | $8 |
| Pre-Tax Income | -$108 | -$111 | -$115 | -$90 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$108 | -$111 | -$115 | -$90 |
| % Margin | – | – | – | – |
| EPS | -0.76 | -0.97 | -1.05 | -0.88 |
| % Growth | 21.6% | 7.6% | -19.3% | – |
| EPS Diluted | -0.76 | -0.97 | -1.05 | -0.88 |
| Weighted Avg Shares Out | 142 | 114 | 110 | 102 |
| Weighted Avg Shares Out Dil | 142 | 114 | 110 | 102 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $7 | $7 | $8 |
| Interest Expense | $3 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$105 | -$110 | -$122 | -$97 |
| % Margin | – | – | – | – |